Uveitis is defined as intraocular inflammation. It is an extraarticular manifestation of many forms of joint disease, which include spondyloarthritis, juvenile idiopathic arthritis, and Behc ßet's disease. Rheumatologists may be asked to consult on the ophthalmologic care of patients with uveitis in order to identify an associated systemic illness. Diagnoses such as spondyloarthritis, sarcoidosis, and interstitial nephritis with uveitis are frequently overlooked by referring ophthalmologists. Alternatively, rheumatologists may be asked to help manage the patient's immunosuppression, including biologic therapy, which can be required to treat a subset of patients with uveitis. This review is intended to provide rheumatologists with the necessary information to facilitate collaboration in the comanagement of patients with uveitis.
Imagine a symphony orchestra in which the conductor cannot coordinate the play of the wind instruments with the strings or percussion. Imagine a basketball or soccer team that has not mastered the concept of passing the ball. Imagine an epidemiologic study in which the statisticians and those who conceptualized the study each had a different understanding of the study's purpose. Many endeavors represent a gestalt for which the anticipated goal requires multiple parts, and the whole is greater than the sum of those parts. Since rheumatologists see patients with multisystem disease, they are well aware of this need for collaboration.
Uveitis, also known as intraocular inflammation, is a prototypical illness that begs for collaboration. Uveitis is often best assessed and optimally treated by an interdisciplinary team. In this review, we seek to prepare rheumatologists with the information necessary to help facilitate the success of this collaborative effort.
Background
The term uvea derives from the Latin word for grape. The Roman anatomists felt that peeling away the outer layer of the eye, the cornea and sclera, left a grape-like structure: the iris, ciliary body, and choroid ( Figure 1 ). Any portion of the uvea can be inflamed, and often the inflammation involves adjacent structures ( Figure 2 ). Anatomic subsets of uveitis include iritis (synonymous with anterior uveitis), iridocyclitis, intermediate uveitis, posterior uveitis (such as choroiditis, retinochoroiditis, and chorioretinitis), and panuveitis. Just as an increased number of leukocytes in the synovial fluid is indicative of synovitis, so is an increase in leukocytes in either the aqueous humor or vitreous humor taken as evidence of uveitis, even though neither the anterior chamber, which is filled with aqueous humor, nor the vitreous cavity is technically a part of the uveal tract.
Uveitis has a prevalence of roughly 1 per 1,000 individuals (1) . Several forms of uveitis are episodic, and the prevalence is usually stated as a point prevalence, meaning that active disease was present at the time of the survey. Despite its relative rarity, uveitis accounts for approximately the same amount of visual morbidity as either macular degeneration or diabetic retinopathy (2) , although the latter 2 diseases are generally more commonly recognized by the public as major causes of visual loss. The duration of some subsets of uveitis probably accounts for this paradox. Both macular degeneration and diabetic retinopathy are diseases that occur toward the end of life. In contrast, uveitis might start in childhood or early adulthood and persist through decades.
The uveitis-rheumatology interface
Patients with uveitis often do need a rheumatologist. As shown in Table 1 , many systemic rheumatic diseases can involve both the joints and the uveal tract. Furthermore, most forms of uveitis are immunemediated and respond to immunosuppression, a type of therapy that is outside the expertise of most ophthalmologists.
Just as arthritis has multiple causes, several etiologic factors have been identified in uveitis. Broad etiologic categories are provided in Table 2 . The majority of patients with uveitis have an immune-mediated process. This is supported by observations of leukocytes in the eye, and by the known ability to produce uveitis in laboratory animals by stimulating the immune response. However, just as the preferred approach to therapy differs between systemic lupus and rheumatoid arthritis, even though both are immune-mediated, so it is likely that the preferred treatment for a form of uveitis, such as that secondary to juvenile idiopathic arthritis (JIA), will differ from the optimal therapy for another form of uveitis, such as that secondary to sarcoidosis. Currently, however, most therapy for noninfectious uveitis is determined more by the severity and anatomic location of the uveitis, rather than its etiology, although some notable exceptions are slowly emerging. Although case reports rarely elucidate pathogenesis, the disease course documented in a physician who survived Ebola infection may reveal clues about the intersection between uveitis and rheumatic diseases (3). The patient contracted Ebola in Africa and was flown to Atlanta for care. Although he experienced multiorgan failure, he survived. Fourteen weeks after presentation, this patient exhibited a severe uveitis, and the treating physicians were able to recover the Ebola virus from his eye, presumably because the eye is an immuneprivileged site. The virus was no longer detectable in the blood. At the time that the uveitis developed, he also had low back pain and enthesitis, symptoms suggestive of a spondyloarthropathy, although the uveitis was intermediate and posterior, locations which are not typically inflamed with ankylosing spondylitis.
When joint swelling is present, we narrow the differential diagnosis on the basis of relevant parameters, such as determination of which joints are involved, whether the disease is symmetric or asymmetric, whether the onset was acute or insidious, and the patient's age and sex. Similarly, subsets of uveitis are recognized by such variables as the specific anatomic portion of the uveal tract that is inflamed, whether the disease is unilateral or bilateral, whether the inflammation is chronic or episodic, whether onset began suddenly or insidiously, and, of course, the patient's age and sex.
Both Behc ßet's disease and ankylosing spondylitis, for example, are associated with uveitis. In patients with Behc ßet's disease or ankylosing spondylitis, low back pain, peripheral arthritis, and diarrhea have been observed. Oral sores are often present in patients with HLA-B27-associated reactive arthritis, just as they are present in Behc ßet's disease. However, the uveitis associated with ankylosing spondylitis almost always affects only one eye at a time, lasts no longer than 3 months, predominantly affects the anterior uveal tract, may cause hypopyon (pus in the anterior chamber of the eye; see Table 3 for a glossary of relevant terms), and tends to be recurrent (4) . The uveitis associated with Behc ßet's disease is also recurrent, but rarely does the eye remain completely uninflamed between attacks. The uveitis associated with Behc ßet's disease is usually bilateral. Moreover, it tends to manifest as both an anterior and an intermediate uveitis (intermediate uveitis being recognized by leukocytes in the vitreous humor) or a panuveitis, often with retinal vasculitis.
While both Behc ßet's disease and ankylosing spondylitis may cause hypopyon, the eye of a patient with ankylosing spondylitis and hypopyon is red, tender, and sensitive to light; fibrin is frequently present in the anterior chamber. In contrast, hypopyon in association with Behc ßet's disease does not necessarily cause pain or redness, and fibrin is rarely present. In some instances, the medical history alone can help distinguish the 2 entities, since review of a patient's history will usually help determine whether one or both eyes are affected or will help ascertain the duration of the eye inflammation. However, other subtleties, such as the presence of retinal vasculitis, require examination by an eye specialist for detection. Thus, the ophthalmologist potentially can help the rheumatologist make a diagnosis, and the rheumatologist can assist the Vitreous humor inflammation can be associated.
* Although this list includes rare causes of arthritis and uveitis, such as Blau syndrome or Whipple's disease, it does not include everything within the differential diagnosis. For example, tuberculosis could cause uveitis and arthritis simultaneously, and some patients with arthritis of unknown cause also develop uveitis. TNF = tumor necrosis factor; NOMID = neonatal-onset multisystem inflammatory disease; PsA = psoriatic arthritis; ANA = antinuclear antibody; PAN = polyarteritis nodosa; GPA = granulomatosis with polyangiitis; LCV = leukocytoclastic vasculitis; GCA = giant cell arteritis. In addition to those listed in Table 1 , also includes multiple sclerosis, tubulointerstitial nephritis with uveitis, and Vogt-KoyanagiHarada syndrome. Trauma
Penetrating trauma can cause sympathetic ophthalmia; surgical trauma, as in cataract surgery, usually causes some self-limited inflammation. "Idiopathic"
Also called primary or undifferentiated uveitis; probably the most common diagnosis in a uveitis clinic.
* HSV = herpes simplex virus; VZV = varicella zoster virus; CMV = cytomegalovirus.
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The coexistence of uveitis and arthritis is not well understood, despite how frequently it occurs, as is shown in Table 1 . Some specific forms of uveitis are discussed in Table 4 . Both the eye and the joint share some biochemical similarities, such as the presence of hyaluronic acid, type II collagen, and aggrecan. Uveitis and arthritis also occur together in several animal models, such as in the SKG mouse model of arthritis (5), adjuvant arthritis in rats (6) , and aggrecan-induced arthritis in BALB/c mice (7) . Their coexistence suggests a shared pathogenesis, but in the aggrecan-induced arthritis model, the mice, which do not produce interferon-c, develop a far more severe uveitis, whereas arthritis in these mice is dramatically ameliorated (7) .
Similarly, characterizing the genetics of the uveitis associated with HLA-B27 shows that ankylosing spondylitis and acute anterior uveitis share a variety of predisposing genes, such as HLA-B27 itself, the interleukin-23 receptor (IL-23R), and endoplasmic reticulum aminopeptidase 1. At the same time, there are identifiable genes, such as IL-6R and IL-18R1 (and probably , that seem to influence solely the susceptibility to acute anterior uveitis (8) .
Differential diagnosis and laboratory testing
The heterogeneity of uveitis has multiple implications. In terms of differential diagnosis, it is obviously critical to distinguish an infection from an immunemediated cause of uveitis. Some infections, such as syphilis and tuberculosis, can be quite variable in terms of their presentation within the eye, and these types of infections are frequently entered into the differential diagnosis. Some of the more common infectious causes of uveitis include herpes simplex, herpes zoster, toxoplasmosis, and cytomegalovirus (the latter usually occuring in an immunocompromised host). Most infections of the uveal tract cause characteristic changes that can be recognized with a slit lamp examination or with indirect ophthalmoscopy. The "partnership" between a rheumatologist and ophthalmologist is, in our opinion, such that the rheumatologist must trust that the ophthalmologist has excluded infection as a potential etiologic factor; both specialists must be aware that a patient who fails to respond to immunosuppression could have an overlooked infectious cause for his or her disease.
Likewise, 2 other etiologic factors, masquerade syndromes and drug-induced disease, are relatively rare, but each has a distinct therapeutic implication. The most common uveitis "masquerade" is probably a B cell lymphoma that is usually confined to the brain and the eye (9,10). It typically occurs bilaterally in patients who are older than age 45 years. This diagnosis can be easily missed. Medications do not usually cause uveitis, but possible culprits may include intravenous bisphosphonates (11), tumor necrosis factor (TNF) inhibitors (12) , checkpoint inhibitors (13) , and several antibiotics (14) .
In rheumatology, distinguishing gout from rheumatoid arthritis as a cause of joint swelling will markedly change the therapeutic strategy. Most forms of noninfectious uveitis are approached with the use of a treatment algorithm that is not impacted by the cause of the uveitis. Two prominent exceptions are Behc ßet's disease and the anterior uveitis associated with JIA. Inflammation predominantly anterior to the lens of the eye. Band keratopathy:
Deposition of calcium in the corneal epithelium. It is a common finding in the uveitis associated with juvenile idiopathic arthritis. Cystoid macular edema:
A common complication of uveitis that affects central vision and is often treated by a local injection of corticosteroid. Flare:
The diffraction of the slit lamp beam caused by the increased protein in the anterior chamber that results when the blood aqueous barrier is disrupted, as in anterior uveitis. Intermediate uveitis:
Inflammation predominantly in the vitreous humor. Technically, neither the vitreous humor nor the anterior chamber is a part of the uveal tract, but leukocytes in either usually indicate a uveitis, just as cells in the synovial fluid usually indicate a synovitis. Keratic precipitates:
The concretions of cells adherent to the endothelium of the cornea, as seen with a slit lamp examination. Large concretions are called "granulomatous" and are seen in such diseases as sarcoidosis, tuberculosis, and herpes zoster infection. Panuveitis:
Inflammation simultaneously in the anterior chamber, the vitreous humor, and the retina and/or choroid. Posterior synechiae:
The adherence of the iris to the lens. This is a nonspecific finding that is nonetheless much more common in some forms of uveitis (such as that associated with HLA-B27 or in sarcoidosis) than in others. Posterior uveitis:
Inflammation that involves the choroid and often adjacent structures, such as the retina. Retinal vasculitis:
An abnormality of retinal vessels, such as increased vascular permeability. Retinal vasculitis is a common feature of many forms of uveitis and does not correlate well with the occurrence of a systemic vasculitis. SUN criteria:
An acronym for the Standardization of Uveitis Nomenclature, an international consortium that helped to define terms related to uveitis. Almost all patients are HLA-A29 positive.
Blau syndrome A very rare autosomal-dominant form of uveitis associated with mutations in the nucleotide binding domain of NOD2, a gene that codes for an important component of the innate immune system which recognizes the bacterial cell wall.
Genotyping identifies the mutations known to be associated with this syndrome.
HLA-B27 related uveitis Typically, a sudden-onset, self-limited (resolves within 3 months), anterior, recurrent, unilateral uveitis. Most uveitis from any cause is anterior, and 50% of those with a sudden onset of anterior uveitis are HLA-B27 positive, most of whom have some form of spondyloarthropathy. Usually can be managed by topical corticosteroids.
HLA-B27 typing; sacroiliac imaging to help diagnose associated spondyloarthritis.
Idiopathic uveitis
The most common diagnosis made in most series of patients from a uveitis clinic. The term is used to mean a form of uveitis that does not fit a diagnostic niche. Other suggested terms include nonclassifiable, undifferentiated, or primary (as opposed to secondary to another condition, such as ankylosing spondylitis).
A diagnosis made when all other diagnoses have been excluded.
JIA-associated uveitis Characteristically, a bilateral, insidious-onset, chronic (lasting longer than 3 months), anterior uveitis, especially likely to occur in patients with JIA who have a pauciarticular, early-onset, ANA-positive form of arthritis.
A positive ANA finding is supportive of the diagnosis, but is neither sensitive nor specific.
Pars planitis A relatively common form of uveitis that usually begins insidiously and causes inflammation in the vitreous humor, resulting in prominent floaters (however, the majority of patients with floaters do not have pars planitis). The disease is named for the pars plana, an anatomic area immediately posterior to the ciliary body and a site where leukocyte concretions are found in this disease.
A clinical diagnosis based on the location of inflammation; occasionally associated with multiple sclerosis, for which a brain MRI is sometimes obtained.
Primary intraocular lymphoma A very rare form of uveitis, usually occurring in individuals older than age 45 years, and presenting as bilateral cells in the vitreous humor, sometimes with subretinal infiltrates, and often in association with central nervous system lymphoma.
Definitive diagnosis is made by characterization of malignant cells in the vitreous humor or on retinal biopsy.
Sarcoidosis
A form of uveitis with "promiscuous" or highly varied presentations, ranging from anterior uveitis to retinal vasculitis with or without chorioretinal lesions. Ocular inflammation and pulmonary disease are the 2 most common initial manifestations of sarcoidosis, and it accounts for a relatively common systemic illness among patients in a uveitis clinic.
Chest computed tomography is the most sensitive test. Biopsy is rarely required if symmetric hilar or mediastinal adenopathy is present. Testing for levels of ACE, lysozyme, and interleukin-2 receptor has questionable specificity and limited sensitivity.
Syphilis
Late secondary or tertiary syphilis are in the differential diagnosis for any patient labeled as having "idiopathic" uveitis.
FTA or comparable test is preferred. RPR can be negative in up to 40% of patients with uveitis secondary to syphilis. Tubulointerstitial nephritis with uveitis A form of uveitis that is typically sudden in onset, bilateral, and mostly anterior with a variable amount of vitreous humor inflammation. The disease has an extremely strong association with HLA-DRB1*0102. Patients are typically systemically ill with fever, myalgias, and arthralgias as well as a markedly elevated sedimentation rate.
Elevation of urine b 2 -microglobulin levels is a sensitive way to support the diagnosis. Renal biopsy is definitive but often not required. Serum blood urea nitrogen or serum creatinine levels have limited sensitivity.
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For Behc ßet's disease, a monoclonal antibody that inhibits TNF is used frequently, because of its dramatic efficacy (15) . For the anterior uveitis associated with JIA, the more frequent use of methotrexate and/or a TNF inhibitor such as adalimumab has improved the prognosis markedly for this disease (16) . The above considerations regarding differential diagnosis obviously could impact the search for an etiology. The rheumatologist is often tasked with finding a systemic immune-mediated cause, but should not be the practitioner who diagnoses an infection or masquerading malignancy as the cause. As is true of differential diagnosis in general, the history is key, and pattern recognition aids greatly in the goal. Some forms of uveitis, such as Behc ßet's disease or Vogt-KoyanagiHarada (VKH) syndrome, are clinical diagnoses that lack a definitive diagnostic laboratory test. Other diagnoses, like Crohn's disease, ulcerative colitis, or sarcoidosis, can be established or supported by biopsy or imaging, but the procedure may be too costly, too toxic (radiation from a computed tomography [CT] scan of a young person), too unlikely to yield positive results, or too uncomfortable (colonoscopy) to recommend on a routine basis. Our practice is to choose tests selectively based on clues gained from the examination or history. For example, multiple areas of serous elevation of the retina can be detected on examination and confirmed by testing with such techniques as optical coherence tomography or fluorescein angiography. The finding is suggestive of a diagnosis of VKH.
The most common systemic disease associated with uveitis is spondyloarthritis. Approximately one-half of all patients with sudden-onset, noninfectious, anterior uveitis in Europe or North America are HLA-B27 positive (17) . Recent studies, one from an emergency room in Dublin, Ireland (18) and another from Spain involving 798 subjects and a collaboration between rheumatologists and ophthalmologists (19) , concluded that roughly 80% of patients with B27-associated acute anterior uveitis have axial spondyloarthritis based on the Assessment of SpondyloArthritis international Society criteria. This observation was attained even though both studies excluded any patient with uveitis who had a known spondyloarthropathy. Spondyloarthritis is less common among those who have anterior uveitis and are HLA-B27 negative, but the diagnosis remains surprisingly frequent (19) . Older studies using more stringent criteria to diagnose spondyloarthritis had also concluded that spondyloarthropathy was endemic among patients with anterior uveitis (4, 20) . Rheumatologists who are unaware of this association will frequently fail to recognize the clinical significance of the chronic inflammatory back pain that afflicts many individuals with anterior uveitis.
Another critical cause of uveitis to appreciate is sarcoidosis. In a study from the Cleveland Clinic, 57% of women older than age 61 years with idiopathic uveitis had normal findings on chest radiography but had chest CT evidence of sarcoidosis (21) . We recently found a similar, slightly lower yield by performing chest CT on patients older than age 40 years with idiopathic Whipple's disease A rare but treatable cause of uveitis in association with arthritis. The presentation in the eye is generally cells in the vitreous humor.
Identification of the causative organism, Tropheryma whippeli, in the vitreous humor or elsewhere.
* JIA = juvenile idiopathic arthritis; ANA = antinuclear antibody; MRI = magnetic resonance imaging; ACE = angiotensin-converting enzyme; FTA = fluorescent treponemal antibody; RPR = rapid plasma reagin; PCR = polymerase chain reaction.
uveitis (22) . In addition, we noted that 21% of those discovered to have sarcoidosis on chest CT also had cardiac sarcoidosis with associated ventricular tachycardia (22) . Thus, recognition of the systemic illness had potentially life-saving implications. A study from Japan reached a similar conclusion about uveitis and cardiac sarcoidosis (23) . While most systemic rheumatic diseases associated with uveitis, such as Behc ßet's disease, are diagnosed on the basis of the clinical presentation, tubulointerstitial nephritis with uveitis (TINU) is another of those easily overlooked entities. Rheumatologists might be asked to see a patient with TINU because the patient has redness in both eyes and photophobia from the anterior uveitis, and the patient is typically systemically ill with fever, myalgias, a markedly elevated erythrocyte sedimentation rate, mild anemia, and mildly abnormal liver enzyme levels (24, 25) . Unless one is cognizant of the diagnosis and requests a measurement of b 2 -microglobulin levels in the urine, the diagnosis is frequently overlooked.
In virtually every series of patients with uveitis, a diagnosis of "idiopathic" disease is the most common etiology noted (26) . Other terms to describe idiopathic uveitis include nonclassifiable disease, primary uveitis, or undifferentiated disease (27) .
Despite the breadth of the differential diagnosis for uveitis, the rheumatologist should be able to take a relatively targeted approach to laboratory testing (28) . The initial examination by the ophthalmologist should reveal any suspicion of a masquerade syndrome or an infectious cause. The detailed history should point to most of the possible associated systemic immunemediated diseases. If the history and clinical examination have failed to point to a probable cause, we screen for syphilis, since this infection can be latent for many years and its uveal manifestations are protean.
In addition, we obtain a chest radiograph, as sarcoidosis might be asymptomatic in the lungs and this is also useful as a screen for tuberculosis. The sensitivity of chest radiography for either ocular tuberculosis or sarcoidosis is probably 50% or lower. Because of the potential exposure to extensive radiation, we usually do not obtain a chest CT scan to search for sarcoid, unless the patient is more than 40 years of age (22) . In the US, we also do not screen for tuberculosis exposure, unless the patient has a specific risk factor for tuberculosis, such as birth outside the US or a history of incarceration (29) . Additional tests might be useful to monitor therapy, such as a complete blood cell count and metabolic panel. Targeted testing is also useful if the presentation suggests a specific entity. For example, we often test for HLA-B27 if the patient presents with unilateral, acute, anterior uveitis. We check urine for the levels of b 2 -microglobulin in patients who present with a bilateral, sudden-onset, anterior uveitis. We consider a diagnosis of multiple sclerosis if the patient relates the presence of neurologic symptoms that might be explained by this diagnosis.
Therapy
The heterogeneity of uveitis has impacted the ability to design clinical trials. The relative rarity of vision-threatening uveitis is such that different etiologies are usually combined into a single clinical trial. However, the manifestations of a disease such as birdshot retinochoroidopathy are such that the end point for treatment differs greatly from the end point for treatment of an inflammation-related entity such as Behc ßet's disease. This challenge in trial design may have contributed to the failure of promising therapies, such as voclosporine (a congener of cyclosporine), secukinumab (anti-IL-17A) (30, 31) , gevokizumab (anti-IL-1b) (32), or intravitreal rapamycin (33) , to show consistent benefit in clinical uveitis trials.
Most practitioners treat uveitis, especially anterior uveitis, initially with topical corticosteroids. Although these are frequently effective, their penetration posterior to the lens is limited. In addition, use of topical corticosteroids can be complicated by cataractogenesis or elevated intraocular pressure. One formulation, difluprednate, has greater ability to treat inflammation posterior to the lens, but it also has a greater tendency to cause a cataract or glaucoma. If topical corticosteroids fail, a locally injected corticosteroid such as triamcinolone can be useful. However, in addition to being an uncomfortable injection, risks include cataract, glaucoma, lid ptosis, and, in rare instances, retinal detachment. Triamcinolone can be injected directly into the vitreous humor, where it has increased benefit and increased risk of intraocular infection or hemorrhage. Oral corticosteroids represent an additional option, but long-term use has toxic effects that are well known to rheumatologists (34) . Antimetabolites, including mycophenolate mofetil, methotrexate, and azathioprine, are popular corticosteroid-sparing drugs that are often utilized by uveitis experts (35) . Additional options include calcineurin antagonists such as cyclosporine or tacrolimus (36) , alkylators like cyclophosphamide, or long-lasting corticosteroid implants delivered either by surgery or injection.
The rheumatologist has a major role to play in managing the therapy in a subset of patients with ocular inflammatory disease. Many ophthalmologists are 1540 ROSENBAUM AND DICK comfortable prescribing oral corticosteroids but rarely resort to steroid-sparing medications (37) . The dosage of prednisone or its equivalent is often such that the treatment has considerable morbidity. A National Institutes of Health-sponsored trial known as MUST (Multicenter Uveitis Steroid Treatment) for patients with noninfectious, intermediate posterior uveitis or panuveitis recently showed the superior efficacy of systemic immunosuppression, as with antimetabolites, compared to a sustained release of fluocinolone into the vitreous humor of the eye. This conclusion was based on findings of visual acuity testing after 7 years of follow-up (38) . Progress in the approval of new therapies for uveitis is hampered by the relative rarity of specific forms of uveitis, by the variety of presumed causes, and by the heterogeneity of outcomes that might define successful therapy. In 2 time-to-treatment failure trials reported in 2016, adalimumab showed a clear-cut benefit in the treatment of noninfectious intermediate, posterior uveitis or panuveitis (39, 40) . In most instances, adalimumab is indicated for patients whose previous treatment with oral corticosteroids was unsuccessful, as well as for patients who have failed treatment with another oral immunosuppressant, such as methotrexate or mycophenolate mofetil. The responsiveness of Behc ßet's disease to adalimumab or infliximab is such that physicians sometimes consider the use of such therapy without conducting a trial of an antimetabolite (41) . Multiple sclerosis (MS) can be associated with intermediate uveitis (42) . Since a diagnosis of MS is a relative contraindication to TNF inhibitor therapy, this diagnosis may need to be excluded prior to the initiation of adalimumab therapy for uveitis.
It is rare to prescribe a biologic agent for anterior uveitis, since in most patients with anterior uveitis, the disease can be controlled with topical medication alone. An exception is the uveitis characteristically associated with a subset of patients with JIA. The typical JIA patient with chronic uveitis develops the disease between ages 2 years and 8 years, and it affects a few joints. The majority of JIA patients are antinuclear antibody positive and are female. The SYCAMORE study tested the efficacy of adalimumab for patients with JIA whose uveitis was active despite treatment with methotrexate and topical corticosteroids (43) . The trial was halted early, since the evidence of benefit was apparent. Another randomized controlled trial used a different outcome measure, quantification of protein in the anterior chamber of the eye, and also concluded that adalimumab was useful for the chronic anterior uveitis associated with JIA (44).
These successes have encouraged additional uveitis trials, such as one assessing the benefit of the JAK inhibitor filgotinib for indications similar to those supporting the use of adalimumab. Many emerging biologics, however, have not been studied rigorously for possible benefit in the treatment of uveitis. Moreover, although uveitis is increasingly targeted in therapeutic trials, a search of the ClinicalTrials.gov website (http:// www.clinicaltrials.gov) in February 2018 identified only 7 current or prior randomized controlled trials involving patients with uveitis. A similar search for clinical trials in patients with rheumatoid arthritis identified 54 trials. Finally, although some ophthalmologists are comfortable prescribing immunosuppression without close physician collaboration, virtually all ophthalmologists lack an infrastructure that is prepared to deal with the systemic infectious complications, which are rare but unavoidable when one suppresses the immune system.
To aid physicians who care for patients with uveitis, several international groups have recently offered guidelines to assist in the care of patients with ocular inflammatory diseases (45, 46) . The FOCUS (Fundamentals of Care for Uveitis) group consisted of 146 international experts who graded the strength of the evidence and who used consensus methodology (45) .
Patients with spondyloarthritis tend to have recurrent episodes of uveitis. As most of these episodes are anterior, last for no more than 3 months, and can be managed with topical corticosteroids alone, the issue of prophylaxis often does not arise. Several medications do reduce the frequency of uveitis. The use of sulfasalazine to prevent attacks of uveitis in patients with spondyloarthritis is supported by the results of randomized controlled trials (47, 48) . Monoclonal antibodies that neutralize TNF, especially adalimumab or infliximab, also prevent attacks of uveitis (49) , but these treatments are generally not prescribed if the sole reason is to prevent attacks of anterior uveitis. At this time, extensive data on how treatments such as secukinumab or tofacitinib affect recurrent uveitis in patients with spondylitis have not been published.
In the future, therapies delivered locally to the eye might become the treatment of choice for ocular inflammation. Locally injected corticosteroid into the eye itself can be very effective, but the therapy is limited, in part because the medication frequently causes cataract and glaucoma. Gene therapy for inherited retinal degeneration has now been approved by the US Food and Drug Administration and is successful, in part, because the injected gene enters a confined space with minimal worries about expression in other tissues (50) . In contrast to that in polyarticular rheumatoid arthritis, successful gene therapy for ocular inflammation needs to target no more than 2 locations. In the decades ahead, 1 or more locally delivered inhibitors of inflammation might become the standard of care for uveitis.
Conclusions
We recognize the challenges in attempting to familiarize oneself with a group of diseases that one cannot fully assess by using the tools in a conventional rheumatology clinic. Moreover, we empathize with the time requirements that impair optimal management of a patient whose illness requires at least 2 subspecialists to confer. Mechanisms that facilitate communication with an ophthalmologist include interdisciplinary clinics and case conferences to discuss patients whose illness lies in the interstices between these 2 disciplines. The gratification of practicing medicine derives primarily from the opportunity to improve the welfare of our patients. That welfare is best served if we as rheumatologists share our knowledge and experience, while welcoming the collaboration of ophthalmologists who, quite literally, have a different view of our patients and their disease. Just as a conductor of a symphony orchestra coordinates multiple musicians, physicians can and should achieve a similar collaboration.
